Progress in the treatment and outcome of pediatric inflammatory bowel disease patients

References

• Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423–439.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.
   PubMed Web of Science ®Google Scholar
• Aujnarain A, Mack DR, Benchimol EI. The role of the environment in the development of pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2013;15:326.
   PubMedGoogle Scholar
• Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489–1499.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009;58:1490–1497.
   PubMed Web of Science ®Google Scholar
• Lehtinen P, Ashorn M, Iltanen S, et al. Incidence trends of pediatric inflammatory bowel disease in Finland, 1987-2003, a nationwide study. Inflamm Bowel Dis. 2011;17:1778–1783.
   PubMed Web of Science ®Google Scholar
• Buderus S, Scholz D, Behrens R, et al. Inflammatory bowel disease in pediatric patients: characteristics of newly diagnosed patients from the CEDATA-GPGERegistry. Dtsch Arztebl Int. 2015;112:121–127.
   PubMed Web of Science ®Google Scholar
• Virta L, Auvinen A, Helenius H, et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease–a nationwide, register-based Finnish case-control study. Am J Epidemiol. 2012;175:775–784.
   PubMed Web of Science ®Google Scholar
• Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60:49–54.
   PubMed Web of Science ®Google Scholar
• Pfeffer-Gik T, Levine A. Dietary clues to the pathogenesis of Crohn’s disease. Dig Dis. 2014;32:389–394.
   PubMed Web of Science ®Google Scholar
• Virta LJ, Ashorn M, Kolho K-L. Cow’s milk allergy, asthma, and pediatric IBD. J Pediatr Gastroenterol Nutr. 2013;56:649–651.
   PubMed Web of Science ®Google Scholar
• Virta LJ, Kautiainen H, Kolho K-L Symptoms suggestive of cow’s milk allergy in infancy and pediatric inflammatory bowel disease. Pediatr Allergy and Immunol. 2016 Feb 17;27:361–367. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Virta LJ, Kolho K-L. The risk of contracting pediatric inflammatory boweldisease in children with celiac disease, epilepsy, juvenile arthritis and type 1diabetes–a nationwide study. J Crohns Colitis. 2013;7:53–57.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Manuel DG, To T, et al. Asthma, type 1 and type 2 diabetes mellitus, and inflammatory bowel disease amongst South Asian immigrants to Canada and their children: a population-based cohort study. PLoS One. 2015 Apr 7;10(4):e0123599. doi:10.1371/journal.pone.0123599.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Schwarz K, Baurecht H, et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol. 2016;137:130–136.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–1207.
   PubMed Web of Science ®Google Scholar
• Levine A, Koletzko S, Turner D, et al. The ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.
   PubMed Web of Science ®Google Scholar
• De Bie CI, Paerregaard A, Kolacek S, et al. Disease phenotype at diagnosis in pediatric Crohn’s disease: 5-year analyses of the EUROKIDS registry. Inflamm Bowel Dis. 2013;19:378–385.
   PubMed Web of Science ®Google Scholar
• Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55:340–361. .
   PubMed Web of Science ®Google Scholar
• Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–1321.
   PubMed Web of Science ®Google Scholar
• Magro F, Langner C, Driessen A, et al. European Society of Pathology (ESP) and the European Crohn’s and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827–851.
   PubMed Web of Science ®Google Scholar
• Hommel KA. Psychosocial and behavioral issues in children and adolescents with IBD: clinical implications. Gastroenterol Hepatol (N Y). 2013;9:189–191.
   PubMedGoogle Scholar
• Mackner LM, Greenley RN, Szigethy E, et al. Psychosocial issues in pediatric inflammatory bowel disease: report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2013;56:449–458.
   PubMed Web of Science ®Google Scholar
• Väistö T, Aronen E, Simola P, et al. Psychosocial symptoms and competence among adolescents with inflammatory bowel disease and their peers. Inflamm Bowel Dis. 2010;16:27–35.
   PubMed Web of Science ®Google Scholar
• Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology. 2013;144:36–49.
   PubMed Web of Science ®Google Scholar
• Guilfoyle SM, Gray WN, Herzer-Maddux M, et al. Parenting stress predicts depressive symptoms in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2014;26:964–971.
   PubMedGoogle Scholar
• Ryan JL, Mellon MW, Junger KWF, et al. The clinical utility of health-related quality of life screening in a pediatric inflammatory bowel disease clinic. Inflamm Bowel Dis. 2013;19:2666–2672.
   PubMed Web of Science ®Google Scholar
• Keerthy D, Youk A, Srinath AI, et al. Effect of psychotherapy on healthcare utilization in children with inflammatory bowel disease and depression. J Pediatr Gastroenterol Nutr. 2016 Mar 28;1. [ Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• Pirinen T, Kolho K-L, Simola P, et al. Parent and self-report of sleep-problems and daytime tiredness among adolescents with inflammatory bowel disease and their population-based controls. Sleep. 2010;33:1487–1493.
   PubMed Web of Science ®Google Scholar
• Pirinen T, Kolho K-L, Ashorn M, et al. Sleep and emotional and behavioral symptoms in adolescents with inflammatory bowel disease. Sleep Disord. 2014;2014:1–5.
   Google Scholar
• Spekhorst LM, Hummel TZ, Benninga MA, et al. Adherence to oral maintenance treatment in adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;62:264–270.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Bousvaros A, Hyams J, et al. Intercenter variation in initial management of children with Crohn’s disease. Inflamm Bowel Dis. 2007;13:890–895.
   PubMed Web of Science ®Google Scholar
• Assa A, Avni I, Ben-Bassat O, et al. Practice variations in the management of inflammatory bowel disease between pediatric and adult gastroenterologists. J Pediatr Gastroenterol Nutr. 2016;62:372–377.
   PubMed Web of Science ®Google Scholar
• Turner D, Travis SPL, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011;106:574–588.
   PubMed Web of Science ®Google Scholar
• Turner D, Levine A, Kolho K-L, et al. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohn´s Colitis. 2014;8:1464–1470.
   PubMed Web of Science ®Google Scholar
• Navas-López VM, Blasco Alonso J, Serrano Nieto MJ, et al. Oral tacrolimus for pediatric steroid-resistant ulcerative colitis. J Crohns Colitis. 2014;8:64–69.
   PubMed Web of Science ®Google Scholar
• Lazzerini M, Martelossi S, Magazzù G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA. 2013;310:2164–2173.
   PubMed Web of Science ®Google Scholar
• Lazzerini M, Martelossi S, Magazzù G, et al. Effect of thalidomide on clinical remission in children and adolescents with ulcerative colitis refractory to other immunosuppressives: pilot randomized clinical trial. Inflamm Bowel Dis. 2015;21:1739–1749.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Mack D. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol. 2011;106:981–987.
   PubMed Web of Science ®Google Scholar
• Zeisler B, Lerer T, Markowitz J, et al. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013;56:12–18.
   PubMed Web of Science ®Google Scholar
• De Bie C, Kindermann A, Escher J. Use of exclusive enteral nutrition in paediatric Crohn’s disease in The Netherlands. J Crohns Colitis. 2013;7:263–270.
   PubMed Web of Science ®Google Scholar
• Punati J, Markowitz J, Lerer T, et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. 2008;14:949–954.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N, et al. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol. 2002;97:928–932.
   PubMed Web of Science ®Google Scholar
• Virta LJ, Kolho KL Trends in early drug therapy in paediatric inflammatory bowel disease in Finland –a nationwide register-based study in 1999-2009. ISRN Gastroenterology. 2012;462642. doi:10.5402/2012/462642. Epub 2012 Aug 16.
   PubMedGoogle Scholar
• Jakobsen C, Paerregaard A, Munkholm P, et al. Pediatric inflammatory bowel disease: increasing incidence, decreasing surgery rate, and compromised nutritional status: A prospective population-based cohort study 2007-2009. Inflamm Bowel Dis. 2011;17:2541–2550.
   PubMed Web of Science ®Google Scholar
• Sunseri W, Hyams JS, Lerer T, et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn’s disease. Inflamm Bowel Dis. 2014;20:1341–1345.
   PubMed Web of Science ®Google Scholar
• Jakobsen C, Munkholm P, Paerregaard A, et al. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators–a population-based study. Inflamm Bowel Dis. 2011;17:1731–1740.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:1124–1129.
   PubMed Web of Science ®Google Scholar
• Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4:1118–1123.
   PubMed Web of Science ®Google Scholar
• De Bie CI, Escher JC, De Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:985–1002.
   PubMed Web of Science ®Google Scholar
• Martín-de-Carpi J, Pociello N, Varea V. Long-term efficacy of adalimumab in paediatric Crohn’s disease patients naïve to other anti-TNF therapies. J Crohns Colitis. 2010;4:594–598.
   PubMed Web of Science ®Google Scholar
• De Ridder L, Waterman M, Turner D, et al. Use of biosimilars in paediatric inflammatory bowel disease: a position statement of the (Porto) ESPGHAN IBD Working Group. J Pediatr Gastroenterol Nutr. 2015;61:503–508.
   PubMed Web of Science ®Google Scholar
• De Ridder L, Rings EHHM, Damen GM, et al. Infliximab dependency in pediatric Crohn’s disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14:353–358.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis. 2009;15:816–822.
   PubMed Web of Science ®Google Scholar
• Kolho K-L, Sipponen T. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2014;49:434–441.
   PubMed Web of Science ®Google Scholar
• Cameron FL, Wilson ML, Basheer N, et al. Anti-TNF therapy for paediatric IBD: the Scottish national experience. Arch Dis Child. 2015;100:399–405.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010;105:1430–1436.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Guerra I, Muñoz-Linares P, et al. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:971–986.
   PubMed Web of Science ®Google Scholar
• Merras-Salmio L, Kolho K-L. Clinical use of infliximab trough levels and antibodies to infliximab in pediatric inflammatory bowel disease patients. J Pediatr Gastroenterol Nutr. 2016 May 2;1. [Epub ahead of print.]
   Google Scholar
• Hämäläinen A, Sipponen T, Kolho K-L. Serum infliximab concentrations in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2013;48:35–41.
   PubMed Web of Science ®Google Scholar
• Aloi M, D’Arcangelo G, Capponi M, et al. Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: efficacy of infliximab as a rescue therapy. Dig Liver Dis. 2015 Jun;47(6):455–459.
   PubMedGoogle Scholar
• Merras-Salmio L, Kolho K-L Six pediatric patients with inflammatory bowel disease treated with TNFα-blocker golimumab. J Pediatr Gastroenterol Nutr. 2016 Feb 16. [ Epub ahead of print.]
   Web of Science ®Google Scholar
• Cameron FL, Garrick V, Russell RK. Ustekinumab in treatment of refractory paediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2016;62:e30.
   PubMed Web of Science ®Google Scholar
• Bishop C, Simon H, Suskind D, et al. Ustekinumab in Pediatric Crohnʼs disease patients. J Pediatr Gastroenterol Nutr. 2016 Feb 4;1. [Epub ahead of print.]
   Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2016 Feb 18. pii: gutjnl-2015-311079. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12:1485–1493.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616–624.
   PubMed Web of Science ®Google Scholar
• De Ridder L, Turner D, Wilson DC, et al. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the Porto pediatric IBD group. Inflammatory Bowel Dis. 2014;20:291–300.
   PubMed Web of Science ®Google Scholar
• Ashworth LA, Billett A, Mitchell P, et al. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis. 2012;18:838–843.
   PubMed Web of Science ®Google Scholar
• Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14–22.
   PubMed Web of Science ®Google Scholar
• Kolho K-L, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:720–725.
   PubMed Web of Science ®Google Scholar
• Fagerberg UL, Lööf L, Lindholm J, et al. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414–420.
   PubMed Web of Science ®Google Scholar
• Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–553.
   PubMedGoogle Scholar
• Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1229–1235.
   PubMed Web of Science ®Google Scholar
• Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207–1212.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kolho K-L. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872–877.
   PubMed Web of Science ®Google Scholar
• Hämäläinen A, Sipponen T, Kolho K-L. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol. 2011;17:5166–5171.
   PubMed Web of Science ®Google Scholar
• Van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis. 2012;18:2018–2025.
   PubMed Web of Science ®Google Scholar
• Mao R, Xiao Y-L, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894–1899.
   PubMed Web of Science ®Google Scholar
• Kolho K-L, Alfthan H, Hämäläinen E. Effect of bowel cleansing for colonoscopy on fecal calprotectin levels in pediatric patients. J Pediatr Gastroenterol Nutr. 2012;55:751–753.
   PubMed Web of Science ®Google Scholar
• Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2012;107:941–949.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Turner D Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis. ISRN Gastroenterol. 2013;179024. doi:10.1155/2013/179024. Epub 2013 Feb 26.
   PubMedGoogle Scholar
• Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637–645.
   PubMed Web of Science ®Google Scholar
• Degraeuwe PL, Beld MP, Ashorn M, et al. Faecal calprotectin in suspected paediatric inflammatory bowel disease –an individual patient data meta-analysis. J Pediatr Gastroenterol Nutr. 2015;60:339–346.
   PubMed Web of Science ®Google Scholar
• Annaházi A, Molnár T, Farkas K, et al. Fecal MMP-9: A new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis. 2013;19:316–320.
   PubMed Web of Science ®Google Scholar
• Kolho K-L, Sipponen T, Valtonen E, et al. Fecal calprotectin, MMP-9 and human beta defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2014;29:43–50.
   PubMed Web of Science ®Google Scholar
• Judd TA, Day AS, Lemberg DA, et al. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011;26:1493–1499.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742–756.
   PubMed Web of Science ®Google Scholar
• Kolho K-L Assessment of disease activity in pediatric ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2016 May 17;1–8. [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kolho K-L. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74–80.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Turner D, Veereman-Wauters G, et al. Rapid test for fecal calprotectin levels in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2012;55:436–439.
   PubMed Web of Science ®Google Scholar
• Elkjaer M, Burisch J, Voxen Hansen V, et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther. 2010;31:323–330.
   PubMed Web of Science ®Google Scholar
• Molander P, Färkkilä M, Salminen K, et al. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014;20:1021–1028.
   PubMed Web of Science ®Google Scholar
• Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohn´s Colitis. 2015;9:33–40.
   PubMed Web of Science ®Google Scholar
• Hukkinen M, Pakarinen M, Merras-Salmio L, et al. Fecal calprotectin in the prediction of postoperative recurrence of Crohn’s disease in children and adolescents. J Ped Surg. 2016 Feb 4. doi:10.1016/j.jpedsurg.2016.01.017. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Zubin G, Peter L. Predicting endoscopic Crohn’s disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis. 2015;21:1386–1391.
   PubMed Web of Science ®Google Scholar
• Gerasimidis K, Nikolaou CK, Edwards CA, et al. Serial fecal calprotectin changes in children with Crohn’s disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol. 2011;45:234–239.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, Guariso G. Crohn’s disease and growth deficiency in children and adolescents. World J Gastroenterol. 2014 Oct 7;20(37):13219–13233.
   PubMed Web of Science ®Google Scholar
• Turner D, Griffiths AM, Mack D, et al. Assessing disease activity in ulcerative colitis: patients or their physicians? Inflamm Bowel Dis. 2010;16:651–656.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Rodemann J, Kip KE, et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2011;17:1008–1014.
   PubMed Web of Science ®Google Scholar
• Turner D, Levine A, Walters TD, et al. Which PCDAI version best reflects intestinal inflammation in pediatric Crohnʼs disease? J Pediatr Gastroenterol Nutr. 2016 Apr 4;1. [Epub ahead of print.]
   Google Scholar
• Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423–433.
   PubMed Web of Science ®Google Scholar
• Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282–2291.
   PubMed Web of Science ®Google Scholar
• Brambilla M, De Mauri A, Lizio D, et al. Cumulative radiation dose estimates from medical imaging in paediatric patients with non-oncologic chronic illnesses. A systematic review. Phys Med. 2014;30:403–412.
   PubMed Web of Science ®Google Scholar
• Civitelli F, Casciani E, Maccioni F, et al. Use of imaging techniques in inflammatory bowel diseases that minimize radiation exposure. Curr Gastroenterol Rep. 2015;17:28.
   PubMedGoogle Scholar
• Ordás I, Rimola J, García-Bosch O, et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut. 2013;62:1566–1572.
   PubMed Web of Science ®Google Scholar
• Chalian M, Ozturk A, Oliva-Hemker M, et al. MR enterography findings of inflammatory bowel disease in pediatric patients. AJR Am J Roentgenol. 2011;196:W810–W816.
   PubMed Web of Science ®Google Scholar
• Giles E, Hanci O, McLean A, et al. Optimal assessment of paediatric IBD with MRI and barium follow-through. J Pediatr Gastroenterol Nutr. 2012;54:758–762.
   PubMed Web of Science ®Google Scholar
• Wallihan DB, Towbin AJ, Denson LA, et al. Inflammatory bowel disease in children and adolescents: assessing the diagnostic performance and interreader agreement of magnetic resonance enterography compared to histopathology. Acad Radiol. 2012;19:819–826.
   PubMed Web of Science ®Google Scholar
• Church PC, Turner D, Feldman BM, et al. Systematic review with meta-analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn’s disease. Aliment Pharmacol Ther. 2015;41:153–166.
   PubMed Web of Science ®Google Scholar
• Piekkala M, Kalajoki-Helmiö T, Martelius L, et al. Magnetic resonance enterography guiding treatment in children with Crohn’s jejunoileitis. Acta Paediatrica. 2012;101:631–636.
   PubMed Web of Science ®Google Scholar
• Sauer CG, Middleton JP, McCracken C, et al. Magnetic resonance enterography healing and magnetic resonance enterography remission predicts improved outcome in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2016;62:378–383.
   PubMed Web of Science ®Google Scholar
• Min SB, Le-Carlson M, Singh N, et al. Video capsule endoscopy impacts decision making in pediatric IBD: a single tertiary care center experience. Inflamm Bowel Dis. 2013;19:2139–2145.
   PubMed Web of Science ®Google Scholar
• Ahmad TM, Greer M-L, Walters TD, et al. Bowel sonography and MR enterography in children. AJR Am J Roentgenol. 2016;206:173–181.
   PubMed Web of Science ®Google Scholar
• Bremner AR, Griffiths M, Argent JD, et al. Sonographic evaluation of inflammatory bowel disease: a prospective, blinded, comparative study. Pediatr Radiol. 2006;36:947–953.
   PubMed Web of Science ®Google Scholar
• Migaleddu V, Quaia E, Scanu D, et al. Inflammatory activity in Crohns disease: CE-US. Abdom Imaging. 2011;36:142–148.
   PubMedGoogle Scholar
• Chiorean L, Schreiber-Dietrich D, Braden B, et al. Ultrasonographic imaging of inflammatory bowel disease in pediatric patients. World J Gastroenterol. 2015;21:5231–5241.
   PubMed Web of Science ®Google Scholar
• Park KT, Crandall WV, Fridge J, et al. Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:946–951.
   PubMed Web of Science ®Google Scholar
• Karve S, Candrilli S, Kappelman MD, et al. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease. J Pediatr. 2012;161:662–670.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:62–68.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Palmer L, Boyle BM, et al. Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis. 2010;16:125–133.
   PubMed Web of Science ®Google Scholar
• Quach P, Nguyen GC, Benchimol EI. Quality improvement in pediatric inflammatory bowel disease: moving forward to improve outcomes. World J Gastroenterol. 2013;19:6367–6374.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Hyams JS, Otley A, et al. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut. 2015;64:438–446. .
   PubMed Web of Science ®Google Scholar
• Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599–608.
   PubMed Web of Science ®Google Scholar